Search 33,000+ CME courses
Back

StatPearls, LLC

  • Biosimilar Pharmaceuticals
  • Infliximab

Infliximab-abda

Infliximab-abda is a biosimilar monoclonal antibody that targets tumor necrosis factor-alpha (TNF- ), a cytokine involved in inflammatory and autoimmune pathophysiology. This activity presents a focused review of infliximab-abda’s mechanism of action, therapeutic indications across dermatology, immunology, gastroenterology, and rheumatology, and relevant contraindications. Particular attention is given to the historical context of anti-TNF- therapy, beginning with FDA approval in 1998 and subsequent dermatologic use in 2002. The activity addresses adverse effects, dosing protocols, and clinically significant drug interactions to support the appropriate administration of infliximab-abda. Strategies to mitigate toxicity while optimizing therapeutic benefit are emphasized. Emphasis is placed on the role of the interprofessional healthcare team in patient selection, monitoring, and long-term management. By presenting current evidence and practical application, this activity supports safe and effective use of infliximab-abda in clinical practice.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AAPA Category 1 Credit™Up to 1.5 creditsAMA PRA Category 1 Credit™Up to 1.5 creditsNursingUp to 1.5 creditsPharmacyUp to 1.5 credits

MOC types

ABS — Accredited CMEUp to 1.5 pointsABOS — Accredited CMEUp to 1.5 pointsABPATH — Lifelong LearningUp to 1.5 pointsABTS — Accredited CMEUp to 1.5 pointsABIM — Medical KnowledgeUp to 1.5 pointsABS — Self-AssessmentUp to 1.5 pointsABP — Lifelong Learning and Self-AssessmentUp to 1.5 pointsABTS — Self-AssessmentUp to 1.5 points

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Cross-Specialty

Relevant across 8 specialties.

Pricing

Fee varies

This provider typically $49–98

See fees on statpearls.com

Listed by the provider

  • Article / monograph / reference
  • Credit · Up to 1.5 credits
  • MOC · Up to 1.5 points
  • Fee varies · this provider typically $49–98
  • Released
    Sep 1, 2026
  • Last day to claim credit
    Sep 1, 2029 3 years left

More from StatPearls, LLC

See all

This provider’s courses closest to this one